Problems and promise of immunological factors as biomarkers for schizophrenia

Biomarkers in Medicine

Volumn 2, Issue 4, 2008, Pages 385-395

  Herberth, M ^a   Schwarz, E ^a   Bahn, Sabine ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Biomarker; Immunology; Psychiatric disorder; Schizophrenia

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CYTOKINE; IMMUNOLOGIC FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 6; NEUROLEPTIC AGENT; SOLUBLE INTERLEUKIN 2 RECEPTOR;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CANNABIS ADDICTION; CELL COMPOSITION; CELL MIGRATION; CELL TYPE; CONFOUNDING VARIABLE; CYTOMEGALOVIRUS; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HEREDITY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; LYMPHOCYTE COUNT; PROTEIN ANALYSIS; REVIEW; SAMPLING; SCHIZOPHRENIA; SMOKING; T LYMPHOCYTE; TOXOPLASMA GONDII;

EID: 54849417615     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.4.385     Document Type: Review

References (102)

1. Thaker GK, Carpenter WT: Advances in schizophrenia. Nat. Med. 7, 667 (2001).
2. Holmes E, Tsang TM, Huang JT et al.: Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3, e327 (2006).
3. Killackey E, Yung AR: Effectiveness of early intervention in psychosis. Curr. Opin. Psychiatry 20, 121-125 (2007).
4. Saha S, Chant D, Welham J, McGrath J: A systematic review of the prevalence of schizophrenia. PLoS Med. 2, e141 (2005).
5. Prilipko LL: Biological studies of schizophrenia in Europe. Schizophr. Bull. 12, 83-100 (1986).
6. Muller N, Ackenheil M: Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 1-33 (1998).
7. Barr CE, Mednick SA, Munk-Jorgensen P: Exposure to influenza epidemics during gestation and adult schizophrenia. A 40-year study. Arch. Gen. Psychiatry 47, 869-874 (1990).
8. Yolken RH, Torrey EF: Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 8, 131-145 (1995).
9. Selten J-P, Kahn RS: Schizophrenia after prenatal exposure to Toxoplasma gondii? Clin. Infect. Dis. 35, 633-634 (2002).
10. Prasad KMR, Shirts BH, Yolken RH, Keshavan MS, Nimgaonkar VL: Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Mol. Psychiatry 12, 105 (2006).
11. Kirch DG: Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 19, 355-370 (1993).
12. Rothermundt M, Arolt V, Bayer TA: Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 15, 319-339 (2001).
13. Newcomer JW: Metabolic syndrome and mental illness. Am. J. Manag. Care 13, S170-S177 (2007).
14. Craddock RM, Lockstone HE, Rider DA et al.: Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS ONE 2, e692 (2007).
15. de Leon J, Diaz FJ: A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 76, 135-157 (2005).
16. Semple DM, McIntosh AM, Lawrie SM: Cannabis as a risk factor for psychosis: systematic review. J. Psychopharmacol. 19, 187-194 (2005).
17. Sopori ML, Kozak W: Immunomodulatory effects of cigarette smoke. J. Neuroimmunol. 83, 148-156 (1998).
18. Moszczynski P, Zabinski Z, Moszczynski P Jr, Rutowski J, Slowinski S, Tabarowski Z: Immunological findings in cigarette smokers. Toxicol. Lett. 118, 121-127 (2001).
19. Zeidel A, Beilin B, Yardeni I, Mayburd E, Smirnov G, Bessler H: Immune response in asymptomatic smokers. Acta Anaesthesiol. Scand. 46, 959-964 (2002).
20. Meliska CJ, Stunkard ME, Gilbert DG, Jensen RA, Martinko JM: Immune function in cigarette smokers who quit smoking for 31 days. J. Allergy Clin. Immunol. 95, 901-910 (1995).
21. Molina-Holgado E, Guaza C, Borrell J, Molina-Holgado F: Effects of cannabinoids on the immune system and central nervous system: therapeutic implications. BioDrugs 12, 317-326 (1999).
22. Hollister LE: Health aspects of cannabis: revisited. Int. J. Neuropsychopharmacol. 1, 71-80 (1998).
23. Sperner-Unterweger B, Whitworth A, Kemmler G et al.: T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr. Res. 38, 61-70 (1999).
24. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 20, 532-545 (2006).
25. Hodge G, Markus C, Nairn J, Hodge S: Effect of blood storage conditions on leucocyte intracellular cytokine production. Cytokine 32, 7-11 (2005).
26. Thavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR: Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J. Immunol. Methods 153, 115-124 (1992).
27. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V: Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-α and leptin. Cytokine 12, 1712-1716 (2000).
28. Riches P, Gooding R, Millar BC, Rowbottom AW: Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-α concentrations. J. Immunol. Methods 153, 125-131 (1992).
29. Weinberg A, Betensky RA, Zhang L, Ray G: Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin. Diagn. Lab. Immunol. 5, 804-807 (1998).
30. Klein A, Ramcharitar S, Christeff N, Nisbett-Brown E, Nunez E, Malkin A: Effect of anticoagulants in vitro on the viability of lymphocytes and content of free fatty acids in plasma. In Vitro Cell. Dev. Biol. 27A, 307-311 (1991).
31. Hinze-Selch D, Pollmacher T: In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav. Immun. 15, 282-318 (2001).
32. Petrovsky N: Towards a unified model of neuroendocrine-immune interaction. Immunol. Cell. Biol. 79, 350-357 (2001).
33. Masek K, Slansky J, Petrovicky P, Hadden JW: Neuroendocrine immune interactions in health and disease. Int. Immunopharmacol. 3, 1235-1246 (2003).
34. Gladkevich A, Kauffman HF, Korf J: Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 559 (2004).
35. Schwarz MJ, Chiang S, Muller N, Ackenheil M: T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. 15, 340-370 (2001).
36. Muller N, Riedel M, Ackenheil M, Schwarz MJ: The role of immune function in schizophrenia: an overview. Eur. Arch. Psychiatry Clin. Neurosci. 249(Suppl. 4), 62-68 (1999).
37. Schwarz MJ, Chiang S, Muller N, Ackenheil M: The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schisophrenia caused by immune mechanisms. Med. Hypothesis 56, 483-486
38. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry (2008) (In Press).
39. Schwarz MJ, Ackenheil M, Riedel M, Muller N: Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci. Lett. 253, 201-203 (1998).
40. Muller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R: Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain-barrier permeability in schizophrenia. Am. J. Psychiatry 156, 634-636 (1999).
41. Iwata Y, Suzuki K, Nakamura K et al.: Increased levels of serum soluble L-selectin in unmedicated patients with schizophrenia. Schizophr. Res. 89, 154-160 (2007).
42. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ: Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. 22, 146-167 (2002).
43. Rosen SD: Ligands for L-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. 22, 129-156 (2004).
44. Hammarberg H, Lidman O, Lundberg C et al.: Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T- and natural killer cells. J. Neurosci 20, 5283-5291 (2000).
45. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M: Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5, 49 (1999).
46. Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M: T-cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl Acad. Sci. USA 101, 8180-8185 (2004).
47. Schwarz MJ, Riedel M, Ackenheil M, Müller N: Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry 47, 29 (2000).
48. Riedel M, Kronig H, Schwarz MJ et al.: Investigation of the ICAM-1 G241A and A469G gene polymorphisms in schizophrenia. Mol. Psychiatry 8, 257-258 (2003).
49. Kronig H, Riedel M, Schwarz MJ et al.: ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia. Neuroimmunomodulation 12, 54-59 (2005).
50. Hackman A, Abe Y, Insull W Jr et al.: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 93, 1334-1338 (1996).
51. Gilvarry CM, Sham PC, Jones PB et al.: Family history of autoimmune diseases in psychosis. Schizophr. Res. 19, 33-40 (1996).
52. Knight J, Knight A, Ungvari G: Can autoimmune mechanisms account for the genetic predisposition to schizophrenia? Br. J. Psychiatry 160, 533-540 (1992).
53. Noy S, Achiron A, Laor N: Schizophrenia and autoimmunity: a possible etiological mechanism? Neuropsychobiology 30, 157-159 (1994).
54. Jones AL, Mowry BJ, Pender MP, Greer JM: Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol. Cell. Biol. 83, 9-17 (2005).
55. Chengappa KN, Nimgaonkar VL, Bachert C, Yang ZW, Rabin BS, Ganguli R: Obstetric complications and autoantibodies in schizophrenia. Acta Psychiatr. Scand. 92, 270-273 (1995).
56. Wright P, Gill M, Murray RM: Schizophrenia: genetics and the maternal immune response to viral infection. Am. J. Med. Genet. 48, 40-46 (1993).
57. Buka SL, Cannon TD, Torrey EF, Yolken RH: Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol. Psychiatry 63, 809-815 (2008).
58. Kim JJ, Lee SJ, Toh KY, Lee CU, Lee C, Paik IH: Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr. Res. 52, 127 (2001).
59. Boyajyan A, Khoyetsyan A, Tsakanova G, Braidwood Sim R: Cryoglobulins as indicators of upregulated immune response in schizophrenia. Clin. Biochem. (2008) (In Press).
60. Ramchand R, Wei J, Ramchand CN, Hemmings GP: Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment. Life Sci. 54, 1579-1584 (1994).
61. Conejero-Goldberg C, Torrey EF, Yolken RH: Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr. Res. 60, 65 (2003).
62. Torrey EF, Leweke MF, Schwarz MJ et al.: Cytomegalovirus and schizophrenia. CNS Drugs 20, 879-885 (2006).
63. Leweke FM, Gerth CW, Koethe D et al.: RH Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254, 4-8 (2004).
64. Taieb O, Baleyte JM, Mazet P, Fillet AM: Borna disease virus and psychiatry. Eur. Psychiatry 16, 3 (2001).
65. Torrey EF, Yolken RH: Toxoplasma gondii and schizophrenia. Emerg. Infect. Dis. 9, 1375-1380 (2003).
66. Yolken RH, Torrey EF: Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol. Psychiatry 13, 470 (2008).
67. Fukuda R, Sasaki T, Kunugi H, Nanko S: No changes in paired viral antibody titers during the course of acute schizophrenia. Neuropsychobiology 40, 57-62 (1999).
68. Delisi LE, Smith SB, Hamovit JR et al.: Herpes simplex virus, cytomegalovirus and Epstein-Barr virus antibody titres in sera from schizophrenic patients. Psychol. Med. 16, 757-763 (1986).
69. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH: Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 60, 466-472 (2003).
70. Dickerson FB, Boronow JJ, Stallings C et al.: Infection with herpes simplex virus Type 1 is associated with cognitive deficits in bipolar disorder. Biol. Psychiatry 55, 588 (2004).
71. Estran C, Brenier-Pinchart MP, Pelletier L, Cesbron-Delauw MF, Pelloux H: Toxoplasma gondii in human astrocytes in vitro: interleukin (IL)-12 and IL-10 do not influence cystogenesis. J. Parasitol. 92, 1108-1110 (2006).
72. Kramer W: Frontiers of neurological diagnosis in acquired toxoplasmosis. Psychiatr. Neurol. Neurochir. 69, 43-64 (1966).
73. Yolken RH, Bachmann S, Ruslanova I et al.: Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin. Infect. Dis. 32, 842-844 (2001).
74. Amminger GP, McGorry PD, Berger GE et al.: RH Antibodies to infectious agents in individuals at ultra-high risk for psychosis. Biol. Psychiatry 61, 1215 (2007).
75. Torrey EF, Bartko JJ, Lun Z-R, Yolken RH: Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 33, 729-736 (2007).
76. Mortensen PB, Norgaard-Pedersen B, Waltoft BL, Sorensen TL, Hougaard D, Yolken RH: Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr. Bull. 33, 741-744 (2007).
77. Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES: Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry 162, 767-773 (2005).
78. Niebuhr DW, Millikan AM, Cowan DN, Yolken R, Li Y, Weber NS: Selected infectious agents and risk of schizophrenia among US military personnel. Am. J. Psychiatry 165, 99-106 (2008).
79. Jones-Brando L, Torrey EF, Yolken R: Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 62, 237 (2003).
80. Vander Kamp H: Nuclear changes in the white blood cells of patients with schizophrenic reaction. A preliminary report. J. Neuropsychiatr. 4, 1-3 (1962).
81. Fessel WJ, Hirata-Hibi M: Abnormal leukocytes in schizophrenia. Arch. Gen. Psychiatry 9, 601-613 (1963).
82. Hirata-Hibi M, Hayashi K: The anatomy of the P lymphocyte. Schizophr. Res. 8, 257-262 (1993).
83. Uranova N, Bonartsev P, Brusov O, Morozova M, Rachmanova V, Orlovskaya D: The ultrastructure of lymphocytes in schizophrenia. World J. Biol. Psychiatry 8, 30-37 (2007).
84. Hirata-Hibi M, Higashi S, Tachibana T, Watanabe N: Stimulated lymphocytes in schizophrenia. Arch. Gen. Psychiatry 39, 82-87 (1982).
85. Rudolf S, Schlenke P, Broocks A et al.: Search for atypical lymphocytes in schizophrenia. World J. Biol. Psychiatry 5, 33-37 (2004).
86. Bruce LC, Peebles AMS: Clinical and experimantal observations on catatonia. J. Ment. Sci. 49, 614-628 (1903).
87. Nikkila HV, Muller K, Ahokas A, Rimon R, Andersson LC: Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr. Res. 49, 99-105 (2001).
88. Nikkila H, Muller K, Ahokas A, Miettinen K, Andersson LC, Rimon R: Abnormal distributions of T-lymphocyte subsets in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr. Res. 14, 215-221 (1995).
89. Nikkila HV, Muller K, Ahokas A, Miettinen K, Rimon R, Andersson LC: Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am. J. Psychiatry 156, 1725-1729 (1999).
90. Bilici M, Tekelioglu Y, Efendioglu S, Ovali E, Ulgen M: The influence of olanzapine on immune cells in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 483-485 (2003).
91. Torrey EF, Upshaw YD, Suddath R: Medication effect on lymphocyte morphology in schizophrenia. Schizophr. Res. 2, 385-390 (1989).
92. Muller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R: Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res. 37, 147-160 (1991).
93. Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Muller N: T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res. 152(2-3),173-180 (2007).
94. + lymphocytes in schizophrenic patients. Schizophr. Res. 31, 49 (1998).
95. De Rosa SC, Roederer M: Eleven-color flow cytometry. A powerful tool for elucidation of the complex immune system. Clin. Lab. Med. 21, 697-712 (2001).
96. Roederer M: How many events is enough? Are you positive? Cytometry A 73, 384-385 (2008).
97. Schwarz E, Bahn S: The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br. J. Pharmacol. 153(Suppl.1), S133-S136 (2008).
98. Riedel M, Spellmann I, Schwarz MJ et al.: Decreased T-cellular immune response in schizophrenic patients. J. Psychiatr. Res. 41, 3-7 (2007).
99. + cells in medication-free patients with schizophrenia. J. Psychiatr. Res. 36, 331 (2002).
100. Kronfol Z, Silva J Jr, Greden J, Dembinski S, Gardner R, Carroll B: Impaired lymphocyte function in depressive illness. Life Sci. 33, 241-247 (1983).
101. Tssai SY, Chen KP, Yang YY et al.: Activation of indices of cell-mediated immunity in bipolar mania. Biol. Psychiatry 45, 989-994 (1999).
102. Craddock RM, Huang JT, Jackson E et al.: Increased a-defensins as a blood marker for schizophrenia susceptibility. Mol. Cell. Proteomics 7(7), 1204-1213 (2008).